Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co‐mutated lung cancers and downregulated mutant‐p53 levels

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

(2023) Haiyan Sun et al.   BMC CANCER

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma

(2022) Natalie I. Vokes et al.   Journal of Thoracic Oncology

Impact of TP53 mutations on EGFR-tyrosine kinase inhibitor efficacy and potential treatment strategy

(2022) Jing Fu et al.   Clinical Lung Cancer

Drugging p53 in cancer: one protein, many targets

(2022) Ori Hassin et al.   NATURE REVIEWS DRUG DISCOVERY

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

(2022) Kai Shang et al.   BMC CANCER

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

(2022) Kai Fu et al.   Journal of Hematology & Oncology

Hidden pharmacological activities of valproic acid: A new insight

(2021) Dhirendra Singh et al.   BIOMEDICINE & PHARMACOTHERAPY

Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy

(2020) Ling Li et al.   Frontiers in Oncology

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

(2020) Kang Qin et al.   BMC CANCER

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)

(2020) Xiang-Meng Li et al.   Clinical Lung Cancer

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells

(2018) Achuth Padmanabhan et al.   Nature Communications

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

(2015) E. M. Alexandrova et al.   NATURE

Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data

(2015) H-W Cheng et al.   Cell Death & Disease

Chaperone-dependent stabilization and degradation of p53 mutants

(2008) P Muller et al.   ONCOGENE

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL